Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin

This is a preview of subscription content, access via your institution.


  1. 1.

    E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40, 332–343 (2011)

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    G. Li Volti, S. Salomone, V. Sorrenti, A. Mangiameli, V. Urso, I. Siarkos, F. Galvano, F. Salamone, Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. Cardiovasc. Diabetol. 14, 62 (2011)

    Article  Google Scholar 

  3. 3.

    L. Abenavoli, Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease. Hepatol. Res. 41, 668 (2011)

    PubMed  Article  Google Scholar 

  4. 4.

    N.E. Gulcelik, A. Usman, A. Gürlek, Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 36, 397–403 (2009)

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    R. Wang, Q. Lu, J. Feng, F. Yin, C. Qin, B. Liu, Y. Liu, X. Liu, Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine 41, 70–75 (2012)

    PubMed  Article  Google Scholar 

Download references

Competing interests

The authors declare that they have no competing interests.

Author information



Corresponding author

Correspondence to Ludovico Abenavoli.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Abenavoli, L., Milic, N. & Capasso, F. Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin. Endocrine 42, 754–755 (2012).

Download citation


  • Insulin Resistance
  • Silymarin
  • Free Fatty Acid Level
  • Silibinin
  • Favorable Safety Profile